INVENTIA HEALTHCARE LIMITED
PharmaINVENTIA HEALTHCARE LIMITED is a pharmaceutical company with 2 FDA-approved products.
INVENTIA HEALTHCARE LIMITED's Key Drugs
INVENTIA HEALTHCARE LIMITED's core commercial portfolio centers on DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE, SITAGLIPTIN AND METFORMIN HYDROCHLORIDE — its most strategically important drugs approved in the last 15 years.
INVENTIA HEALTHCARE LIMITED's Recent FDA Approvals
New NDA/BLA approvals for INVENTIA HEALTHCARE LIMITED over the last two years — novel drugs only, excluding generics and label supplements.
INVENTIA HEALTHCARE LIMITED's Therapeutic Areas
Disease areas where INVENTIA HEALTHCARE LIMITED has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
INVENTIA HEALTHCARE LIMITED Pipeline Snapshot
Active clinical trials for INVENTIA HEALTHCARE LIMITED across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- -
- Latest
- -
- Applications
- 4